Synsam AB (publ) (SYNSAM.ST)
SEK 44.4
(-1.99%)
SEK 44.4
(-1.99%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 5.9 Billion SEK | 10.39% |
| 2022 | 5.34 Billion SEK | 13.13% |
| 2021 | 4.72 Billion SEK | 22.48% |
| 2020 | 3.86 Billion SEK | 2.09% |
| 2019 | 3.78 Billion SEK | 10.87% |
| 2018 | 3.41 Billion SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.52 Billion SEK | 2.84% |
| 2024 Q2 | 1.72 Billion SEK | 13.28% |
| 2023 Q2 | 1.56 Billion SEK | 10.99% |
| 2023 FY | 5.9 Billion SEK | 10.39% |
| 2023 Q4 | 1.47 Billion SEK | 2.0% |
| 2023 Q3 | 1.45 Billion SEK | -7.41% |
| 2023 Q1 | 1.41 Billion SEK | -2.35% |
| 2022 Q1 | 1.18 Billion SEK | -9.12% |
| 2022 Q4 | 1.44 Billion SEK | 9.55% |
| 2022 Q3 | 1.31 Billion SEK | -5.72% |
| 2022 Q2 | 1.39 Billion SEK | 17.96% |
| 2022 FY | 5.34 Billion SEK | 13.13% |
| 2021 Q1 | 1.03 Billion SEK | -5.31% |
| 2021 FY | 4.72 Billion SEK | 22.48% |
| 2021 Q2 | 1.21 Billion SEK | 17.31% |
| 2021 Q4 | 1.3 Billion SEK | 10.97% |
| 2021 Q3 | 1.17 Billion SEK | -3.05% |
| 2020 FY | 3.86 Billion SEK | 2.09% |
| 2020 Q3 | 972 Million SEK | 15.3% |
| 2020 Q1 | 871.5 Million SEK | 0.0% |
| 2020 Q4 | 1.09 Billion SEK | 12.35% |
| 2020 Q2 | 843 Million SEK | -3.27% |
| 2019 FY | 3.78 Billion SEK | 10.87% |
| 2018 FY | 3.41 Billion SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AddLife AB (publ) | 9.68 Billion SEK | 39.029% |
| Biotage AB (publ) | 1.86 Billion SEK | -217.132% |
| Bonesupport Holding AB (publ) | 591.07 Million SEK | -899.024% |
| Doxa AB (publ) | 9.9 Million SEK | -59546.465% |
| Elekta AB (publ) | 18.11 Billion SEK | 67.41% |
| iZafe Group AB (publ) | 1.82 Million SEK | -323994.402% |
| Ortivus AB (publ) | 84.08 Million SEK | -6922.99% |
| Ortivus AB (publ) | 84.08 Million SEK | -6922.99% |
| Q-linea AB (publ) | 4.44 Million SEK | -132895.495% |
| S2Medical AB (publ) | 6.97 Million SEK | -84603.872% |